Affiliation:
1. Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea
Abstract
Nonalcoholic fatty liver disease (NAFLD) can lead to liver fibrosis and cirrhosis. Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. In addition to reducing blood glucose levels and body weight, GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. Additionally, GLP-1RAs have a good safety profile with minor side effects, such as nausea and vomiting. Overall, GLP-1RAs show promise as a potential treatment for NAFLD, and further studies are required to determine their long-term safety and efficacy.
Funder
National Research Foundation of Korea
Korea Medical Institut
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference65 articles.
1. Devarbhavi, H., Asrani, S.K., Arab, J.P., Nartey, Y.A., Pose, E., and Kamath, P.S. (2023). Global burden of Liver Disease: 2023 Update. J. Hepatol., in press.
2. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease;Kang;Clin. Mol. Hepatol.,2021
3. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease;Rinella;Hepatology,2023
4. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease;Bugianesi;Am. J. Gastroenterol.,2005
5. Metformin in the treatment of patients with non-alcoholic steatohepatitis;Uygun;Aliment. Pharmacol. Ther.,2004
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献